Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman Disease

Exclusion Criteria10

• Subjects who have undergone major surgery within 4 weeks prior to the first dose of the study;
• Subjects who have received radiotherapy within 4 weeks prior to the first dose of the study;
• Subjects with a history of myocardial infarction within the past year;
• Patients with New York Heart Association (NYHA) Class 3 or 4 congestive heart failure, or a history of NYHA Class 3 or 4 congestive heart failure;
• Pregnant or lactating women;
• Patients who cannot strictly practice contraception after participating in the study;
• Abnormal liver and kidney function: creatinine level ≥176.8 μmol/L (2 mg/dL), transaminase and bilirubin levels more than 2 times the upper limit of normal
• Abnormal blood counts: absolute neutrophil count less than 1×10\^9/L, platelet count less than 50×10\^9/L;
• Patients or their families who cannot understand the conditions and objectives of the study;
• Any other situation where the investigator considers the patient unsuitable to participate in this trial.